Complications of Diabetes: Screening and Prevention. Dr Martin McIntyre Consultant Physician Royal Alexandra Hospital Paisley
|
|
- Camilla Morton
- 5 years ago
- Views:
Transcription
1 Complications of Diabetes: Screening and Prevention Dr Martin McIntyre Consultant Physician Royal Alexandra Hospital Paisley
2 Diabetic Complications Microvascular: Retinopathy Nephropathy Neuropathy Macrovascular: Coronary heart disease (CHD) Cerebrovascular disease (CVD) Peripheral vascular disease (PVD)
3 Type 2 diabetes is NOT a mild disease Diabetic Retinopathy Leading cause of blindness in working age adults 1 Diabetic Nephropathy Leading cause of end-stage renal disease 2 Stroke 2 to 4 fold increase in cardiovascular mortality and stroke 3 Cardiovascular Disease 8/10 diabetic patients die from CV events 4 Diabetic Neuropathy Leading cause of non-traumatic lower extremity amputations 5
4 Macrovascular disease at diagnosis in Type 2 diabetes Cerebrovascular disease Abnormal ECG 1% 18% 75% of all deaths in people with Type 2 diabetes are due to cardiovascular disease Hypertension 35% Absent foot pulses 13% Intermittent claudication 3% UKPDS Group. Diabetes Res 1990; 13: 1 11.
5 Type 2 diabetes the microvascular burden is already present at diagnosis Retinopathy 1 21% Nephropathy 2 18% Erectile dysfunction 1 20% Neuropathy 1 12% 1. UKPDS Group. Diabetes Res 1990; 13: The Hypertension in Diabetes Study Group. J Hypertens 1993; 11:
6 Retinopathy Specific for diabetes Type 1 and type 2 diabetes Related to duration of diabetes and control Individual risk factors (?genetic) Commonest cause of preventable blindness <65 year old Other Diabetic Eye Diseases Cataracts Glaucoma
7 Normal Retina
8 Preproliferative Retinopathy
9 Proliferative Retinopathy
10 Vitreous Haemorrhage
11 Cataract
12 Retinopathy - Prevention Good diabetes control Type 1 diabetes (DCCT, 1993) Type 2 diabetes (UKPDS, 1998) ACE inhibitors Type 1 diabetes (Lewis et al, 1993) Type 2 diabetes (HOPE, 2000) Early referral to ophthalmologist
13 DCCT - New Retinopathy Percentage of Patients Conventional P<0.001 Intensive Year of Study NEJM 1993;329:977-86
14 DCCT - Progressive Retinopathy Percentage of Patients Conventional P<0.001 Intensive Year of Study NEJM 1993;329:977-86
15 Nephropathy Specific for diabetes Type 1 and type 2 diabetes Related to duration of diabetes and control Associated with retinopathy Commonest cause of ESRD Progressive Microalbuminuria (30-300mg/24hr, albustix -ve) Albuminuria (>300mg/24hr, albustix +ve) Renal impairment (egfr <60mL/min) Dialysis (Transplantation)
16
17 Nephropathy - Prevention Good diabetes control Type 1 diabetes (DCCT, 1993) Type 2 diabetes (UKPDS, 1998) Good blood pressure control (esp. ACEi) Type 1 diabetes (Lewis et al, 1993) Type 2 diabetes (HOPE, 2000) Early referral to nephrologist
18 DCCT - New Microalbuminuria Percentage of Patients Conventional P<0.04 Intensive Year of Study NEJM 1993;329:977-86
19 Neuropathy Clinical Syndromes Chronic sensory neuropathy Acute painful neuropathy Proximal motor neuropathy (amyotrophy) Diffuse motor neuropathy Focal neuropathy Autonomic neuropathy
20 Neuropathy - Prevention Good diabetes control (DCCT, UKPDS) Neuropathy - Treatment Improve diabetes control Anti-depressants (amitriptyline, duloxetine) Anti-epileptics (gabapentin, pregabalin) Axain cream Acupuncture
21 DCCT - Neuropathy Percentage of Patients Intensive Conventional P<0.001 P=0.04 P< Neurological Examination Autonomic- Nerve Study Nerve-Conduction Study NEJM 1993;329:977-86
22 Macrovascular Disease Coronary Heart Disease (CHD) Angina Myocardial infarction PTCA CABG Cerebrovascular Disease (CVD) Stroke TIA Peripheral Vascular Disease (PVD) Intermittent claudication Ulceration Gangrene Amputation
23 Annual Incidence of CVD (per 1000) Cardiovascular Disease DM DM DM DM DM DM Males Females The Framingham Study Kannel and McGee. Circulation 1979
24 Coronary Heart Disease Fatal or non-fatal MI (%) MI +MI Non-DM -MI +MI DM Haffner SM et al. NEJM (1998) 339:
25 Glycaemic Control
26 UKPDS 3867 patients with type 2 DM randomised Conventional control Target: FPG<15mmol/l n=1138 Achieved: HbA1c 7.9% v Intensive control Target: FPG <6mmol/l Achieved: HbA1c 7.0% Sulphonylurea: n=1234 Insulin: n=1156 Lancet (1998) 352:
27 UKPDS Total deaths: 702 (18%) Cardiovascular deaths: 402 (57%) Cancer deaths: 170 (24%) Diabetes deaths: 12 (2%) Accidental deaths: 7 (1%) Other deaths: 111 (16%) Lancet (1998) 352:
28 UKPDS - Glycaemic Control Aggregate Endpoint Log-rank p Any diabetes-related endpoint Diabetes-related deaths 0.34 All-cause mortality 0.44 Myocardial infarction Stroke 0.52 Amputation or death from PVD 0.15 Microvascular Favours Favours Intensive Conventional Single Endpoints Fatal myocardial infarction 0.63 Non-fatal myocardial infarction 0.79 Lancet (1998) 352:
29 Cardiovascular Death HR 0.62 (95% CI 0.49, 0.77) p< Zinman B., Wanner C., Lachin J.M., et al. N Engl J Med 2015; 373:
30 Major Adverse Cardiovascular Events (MACE) LEADER Trial Investigators N Engl J Med 2016; 375:
31 Blood Pressure Control
32 UKPDS (HDS) 1148 hypertensive patients with type 2 DM Tight control (<150/85) v Less tight control (<180/105) BMJ (1998) 317:
33 UKPDS (HDS) Achieved blood pressure: Tight control 144/82 Less tight control 154/87 Clinical end point Any diabetes related end point Deaths related to diabetes All cause mortality Myocardial infarction Stroke Peripheral vascular disease Microvascular disease P value Favours tight control 1 10 Favours less tight control BMJ (1998) 317:
34 Hypertension Optimal Treatment (HOT) Trial 18,790 Patients 50 y.o. (8% DM = 1,501) Felodipine at baseline Adding ACEi, β-blocker, Diuretic Blood Pressure Target DBP Achieved Aspirin 75mg v placebo <90mmHg 144/85 <85mmHg 141/83 <80mmHg 139/81 Hansson et al. Lancet (1998) 351:
35 Hypertension Optimal Treatment (HOT) Trial Subgroup with Diabetes Mellitus Events/1000pt-yrs 30 51% (p=0.005) 37% (p=0.045) 67% (p=0.016) 43% (p=0.068) <90 <85<80 <90 <85<80 <90 <85<80 <90<85<80 Major CV inc Silent CV Total Events... MI Mortality Mortality Hansson et al. Lancet (1998) 351:
36 Antiplatelet Therapy
37 Aspirin in type 2 DM 2 o Prevention: Antiplatelet Trialists Collaboration Meta-analysis of 145 randomised trials in DM and non-dm Vascular Events (% of patients) % RRR p< ConαP non-dm 17% RRR p<0.002 ConαP DM BMJ (1994) 308: 71-72,
38 Hypertension Optimal Treatment (HOT) Trial Events/1000pt-yrs % (p=0.03) 36% (p=0.002) 2% (p=0.88) 7% (p=0.36) 0 P ASA P ASA P ASA P ASA Major CV Events All MI All CVA Total Mortality NB relative benefit of ASA on major CV events was about the same in patients with DM Hansson et al. Lancet (1998) 351:
39 U.S. Physicians Health Study 22,071 U.S. physicians without CV disease Aspirin 325mg v placebo 60% RRR 5yr risk of MI (%) DM DM +Asp 40% RRR o DM o DM +Asp NEJM (1989) 321:
40 Antiplatelet Therapy SIGN 116, March 2010, Updated September 2013
41 Lipid Control
42 Lipid Control in Type 2 DM 2 o Prevention 0 Diabetes RRR (%) CARE LIPID All Three VA-HIT 4S
43 Lipid control in type 2 DM Name of trial Patients No. Intervention MRC/BHF HPS CHD risk (29% DM) 20,536 Simvastatin ALLHAT HBP (35% DM) 10,362 Pravastatin ASCOT HBP (sig. DM) 9,000 Atorvastatin CARDS DM+RF ( o vasc. dis.) 2,000 Atorvastatin ASPEN DM ± vasc. dis. 2,250 Atorvastatin FIELD DM ± vasc. dis. 9,000 Fenofibrate LDS DM o vasc. dis. 5,000 Cerivastatin/ Fenofibrate
44 Lipid control in type 2 DM European Task Force (July 1998): Chol>5.0mmol/l; 10yr CHD risk >20% Joint British Societies (Dec 1998): Chol>5.0mmol/l; 10yr CHD risk >30% BHS (Sept 1999): Chol>5.0mmol/l; 10yr CHD risk >30% SIGN (Jan 2000): Chol>5.0mmol/l; 10yr CHD risk >30% SIGN (Nov 2001): Chol>5.0mmol/l; 10yr CHD risk >30% N.B. 10yr CHD risk >15% when affordable
45 Cardiovascular Risk Assessment Dundee Risk Disk Joint European Task Force Charts Joint British Societies Charts and Disk New Zealand Charts Sheffield Tables Bayer plc HeartScore Computer Programme Yudkin and Chaturvedi Charts
46 Lipid control in type 2 DM European Task Force (July 1998): Chol>5.0mmol/l; 10yr CHD risk >20% Joint British Societies (Dec 1998): Chol>5.0mmol/l; 10yr CHD risk >30% BHS (Sept 1999): Chol>5.0mmol/l; 10yr CHD risk >30% SIGN (Jan 2000): Chol>5.0mmol/l; 10yr CHD risk >30% SIGN (Nov 2001): Chol>5.0mmol/l; 10yr CHD risk >30% N.B. 10yr CHD risk >15% when affordable SIGN (March 2010): Age >40; Simva 40mg or Atorva 10mg
47 The Diabetic Foot Feet are at risk from microvascular (neuropathy) and/or macrovascular disease (PVD) Annual foot examination Skin condition (infection, ulceration) Deformity (claw toes, Charcot joint) Peripheral pulses (dorsalis pedis, posterior tibial) Fine touch (10g monofilament) Vibration (tuning fork, neurosethesiometer) Ankle reflexes
48 The Diabetic Foot
49 The Diabetic Foot
50 Foot ulcers Prevention always better than cure therefore CPR for feet. Check Protect Refer
51 Screening in Practice The following should be done annually: 1. Retinopathy screening - Diabetologist - Optometrist - Ophthalmologist - G.P. - Retinal camera 2. Foot examination - Diabetologist - Chiropodist - Practice Nurse 3. HbA1c - Aiming for <58mmol/mol
52 Screening in Practice 4. Microalbuminuria screening EMU for albumin/creatinine ratio (ACR) Repeat to confirm +/- ACEi or ARB 5. Blood pressure Aiming for <140/80 (<130/80) 6. Lipids Age >40yrs Simvastatin 40mg or Atorvastatin 10mg
53 If you have been Thank you for listening
Complications of Diabetes: Screening and Prevention
Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationAmerican Diabetes Association Standards of Medical Care in Diabetes 2017: Focus on Complications
American Diabetes Association Standards of Medical Care in Diabetes 2017: Focus on Complications Juan Pablo Frias, M.D., FACE President and CEO, National Research Institute, Los Angeles, CA Clinical Faculty,
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationDiabetes Complications. Rezvan Salehidoost, M.D., Endocrinologist
Diabetes Complications Rezvan Salehidoost, M.D., Endocrinologist Different Diabetes Complications Macro vascular Micro vascular Infections Macro vascular Complications Macro-vascular Complications Ischemic
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationDIABETES MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: DIABETES MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN DIABETES MEASURES GROUP: #1. Diabetes: Hemoglobin A1c Poor Control #2. Diabetes: Low Density Lipoprotein (LDL-C)
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationDiabetic & Complications. Dr. A K Viswanath Consultant Diabetologist
Diabetic & Complications Dr. A K Viswanath Consultant Diabetologist Outline Challenges in diabetes How do we fare? Diabetes complications Improving outcomes in diabetes Types of Diabetes Type-1 DM Genetic
More informationPeripheral Arterial Occlusive Disease- The Challenge in patients with diabetes
Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes Ashok Handa Reader in Surgery and Consultant Surgeon Nuffield Department of Surgery University of Oxford Introduction Vascular
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationDiabetes Prevention & Management of Complications
Diabetes Prevention & Management of Complications Dr Ketan Dhatariya Consultant in Diabetes and Endocrinology NNUH The Planet is Changing IFCC (mmol/mol) = (current value (%) * 10.93) - 23.50 (reported
More informationUpdate on Diabetes. Ketan Dhatariya. Why it s Not Just About Glucose Lowering Any More. Consultant in Diabetes NNUH
Update on Diabetes Why it s Not Just About Glucose Lowering Any More Ketan Dhatariya Consultant in Diabetes NNUH The Story So Far.. DCCT Retinopathy Neuropathy Nephropathy Intensive glucose control in
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationMicrovascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More informationCV Risk Management in Diabetes Mellitus
CV Risk Management in Diabetes Mellitus J R Minkoff MD, FACP Endocrinology Clinical Professor of Family and Community Medicine University of California, San Francisco Mr. B 40 y/o Latino male c/o fatigue,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME QOF indicator area: Diabetes Briefing paper Potential output: Recommendations
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationHanyang University Guri Hospital Chang Beom Lee
Hanyang University Guri Hospital Chang Beom Lee Meal prayer, Van Brekelenkam 17 th C Introduction 2012 ADA/EASD Position Statement Proper Patients for Pioglitazone β-cell Preservation by Pioglitazone Benefit
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationHIHIM Clinical Cocepts for Managers 7/31/2009. Fernando Vega, MD 1
Fernando Vega, MD HIHIM 409 July 31, 2008 Hyperglycemia characterized by relative or absolute lack of insulin secretion Varying degrees of insulin resistance Often associated with symptoms: polyruia, polydipsia,
More informationCardiovascular risk reduction in diabetes Lipids (NICE CG181)
Cardiovascular risk reduction in diabetes Lipids (NICE CG181) Primary Prevention T1DM Offer Atorvastatin 20mg if >40 years old Diabetes duration >10 years Established nephropathy Other CVS risk factors
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationTraitements associés chez l hypertendu: Statines, Aspirine
Traitements associés chez l hypertendu: Statines, Aspirine Pr Jean-Jacques Mourad CHU Avicenne, Université Paris 13, Bobigny DU HTA, Mars 2012 jean-jacques.mourad@avc.aphp.fr Global Mortality 2000: Impact
More informationDiabetes Mellitus: Evaluation and Care Management
Diabetes Mellitus: Evaluation and Care Management Michael King, MD Assistant Professor Residency Program Director University of Kentucky Dept. of Family & Community Medicine Learning Objectives 1. Review
More informationManagement of Cardiovascular Disease in Diabetes
Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationNew indicators to be added to the NICE menu for the QOF and amendments to existing indicators
New indicators to be added to the for the QOF and amendments to existing indicators 1 st September 2015 Version 1.1 This document was originally published on 3 rd August 2015, it has since been updated.
More informationCauses of death in Diabetes
Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meetings 1 st and 2 nd September 2016 - London and Leeds Prof Sunil
More informationUpdate sulla terapia antiipertensiva e antiaggregante nel paziente cardiometabolico
Update sulla terapia antiipertensiva e antiaggregante nel paziente cardiometabolico G. Mazzanti UO Cardiologia Ospedale SS. Annunziata, Cento (FE) AUSL di Ferrara Antiplatelet therapy Aspirin Aspirin:
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationDiabetes Control and Complications in Public Hospitals in Malaysia
ORIGINAL ARTICLE Diabetes Control and Complications in Public Hospitals in Malaysia Mafauzy M. FRCP For the Diabcare-Malaysia Study Group, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian,
More informationCardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes
Cardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes Following this presentation, you will be able to: Describe the relationship between major CV risk factors and CVD outcomes Select
More informationGlucose and CV disease
Glucose and CV disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationAmerican Academy of Insurance Medicine
American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationHot Topics in Diabetic Kidney Disease a primary care perspective
Hot Topics in Diabetic Kidney Disease a primary care perspective DR SARAH DAVIES GP PARTNER WITH SPECIAL INTEREST IN DIABETES, CARDIFF DUK CLINICAL CHAMPION NB MEDICAL HOT TOPICS PRESENTER AND DIABETES
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More information130/80 vs. 140/90 If nephropathy is present the target should be 120/ /10/07
DG van Zyl Macro vascular Micro vascular Neuropathy Infections Genetic susceptibility *Repeated acute changes in cellular metabolism Hyperglycemia Tissue damage **Cumulative long term changes in stable
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationIndicator Points Payment stages. HF 1: The practice can produce a register of patients with 4 heart failure
Heart failure Indicator Points Payment stages Records HF 1: The practice can produce a register of patients with 4 heart failure Initial diagnosis HF 2: The percentage of patients with a diagnosis of heart
More informationSTANDARDS OF MEDICAL CARE IN DIABETES 2014
STANDARDS OF MEDICAL CARE IN DIABETES 2014 I. CLASSIFICATION AND DIAGNOSIS Classification of Diabetes Type 1 diabetes β-cell destruction Type 2 diabetes Progressive insulin secretory defect Other specific
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationGli endpoint micro-vascolari nei trial di outcome cardiovascolare
Gli endpoint micro-vascolari nei trial di outcome cardiovascolare Giorgio Sesti University Magna Graecia of Catanzaro ITALY Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di aver ricevuto
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ray K K, Seshasai S R K, Wijesuriya S,
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationBlood pressure treatment target in diabetes. Should it be <130 mmhg?
Blood pressure treatment target in diabetes Should it be
More informationSlide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now
Slide 1 A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for
More informationDiabetes and Hypertension
Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationACCORD, ADVANCE & VADT. Now what do I do in my practice?
ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationA Fork in the Road: Navigating Through New Terrain
A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationBest Medical Therapy for asymptomatic carotid disease
Best Medical Therapy for asymptomatic carotid disease Richard Bulbulia Consultant Vascular Surgeon and Co-PI ACST-2 MRC Population Health Research Unit CTSU, Nuffield Department of Population Health University
More informationCalculating RR, ARR, NNT
Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationCKD & HT. Anne-Marie Angus
CKD & HT Anne-Marie Angus Hypertension definitions Persisting BP >140/90 and HBPM >135/85 Stage 1 >140/90 (HBPM >135/85) Stage 2 >160/100 (HBPM >150/90) Severe >180/100 White coat HT Why treat? A major
More informationMicrovascular Complications in Diabetes:
Microvascular Complications in Diabetes: Perspectives on Glycemic Control to Prevent Microvascular Complications Discussion Outline: Glycemia and Microvascular Compliations Clinical Trials - A Brief History
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More information